The Global Endoscopic Retrograde Cholangiopancreatography Devices Market is expected to grow with a CAGR of 5.9% in the forecast period of 2021 to 2028. The years considered for the study are as mentioned below.

Access Full Report @ https://www.databridgemarketresearch.com/reports/global-endoscopic-retrograde-cholangiopancreatography-devices-market

The global endoscopic retrograde cholangiopancreatography devices market is highly consolidated. The market has witnessed increased strategic developments owing to favorable market scenarios. 

The major players dealing in the global endoscopic retrograde cholangiopancreatography devices market are introducing a strong range of devices, launching new products, and adopting strategic initiatives such as acquisition and agreement. This helped companies to maximize sales with an enhanced product portfolio.

For instance,

• In October 2020, Olympus Corporation announced that it had launched two ERCP stone management devices, StoneMasterV and VorticCatrchV endotherapy devices, which will increase efficiency in bile duct stone management and has helped the company to generate revenue further

Olympus Corporation is the dominating player in the global endoscopic retrograde cholangiopancreatography devices market. The other key players existing in the market includes are Boston Scientific Corporation, Medtronic, BD, Ambu Inc., CONMED Corporation, HOBBS MEDICAL, INC., FUJIFILM Corporation, TeleMed, Systems Inc., Merit Medical Systems, Cook, KARL STORZ, Johnson & Johnson Services, Inc., HOYA Corporation, Medi-Globe GmbH, STERIS, Shaili Endoscopy, Hospiline Equipments among others.

Olympus Corporation

Olympus Corporation was established in 1919 and headquartered in Tokyo, Japan. The company's main focus is on creating innovative opto-digital solutions in healthcare, life-science and provides advanced, minimally invasive therapeutic and diagnostic technologies around the globe. The company has business segments including Endoscopic Solution, Therapeutic Solution, Scientific Solution, and Others, in which the market-focused segment lies under Endoscopic Solution. The company also provides various product categories, including Medical Systems, Life Science Solutions, and Industrial Solutions, in which the market focus products lie under the Medical Systems category. The company is engaged in developing ERCP devices and has taken initiatives to expand its product portfolio.

For instance,

• In May 2018, Olympus Corporation entered into a co-development agreement with ai4gi Solutions Inc. This agreement aimed to improve clinical outcomes, reduce overall costs and enhance the quality of life for patients.

The company has a wide presence in the Americas, Europe, the Middle East and Africa, Asia-Pacific. The company also has subsidiaries such as Gyrus ACMI, Inc. (U.S.), Olympus America Inc. (America), Olympus Biotech International Ltd (Ireland), Olympus Life and Material Science Europa GmbH (Germany), Olympus Medical Equipment Services America Inc. (U.S.) and others.

Boston Scientific Corporation

Boston Scientific Corporation was found in 1979, headquartered in Massachusetts, U.S. The company engages in the development, manufacture, and marketing of medical devices used in interventional medical specialties. It has the following business segments: Medical-Surgical (MedSurg), Rhythm and Neuro and Cardiovascular, in which Medical-Surgical (MedSurg) is the market focused segment. The company also provides various product categories, including Electrophysiology, Female Pelvic Medicine, Gastroenterology, Gastrointestinal Surgery, Interventional Cardiology, Interventional Radiology, Neurology Surgery, Orthopedic Surgery, Pain Medicine, Pulmonology, Urology, Vascular Surgery, in which the market focus products lie under Gastroenterology. The company has initiated many strategic initiatives to expand its ERCP market.

For instance,

• In January 2021, Boston Scientific Corporation announced that it has agreed to acquire Preventice Solutions, Inc. The acquisition will help the company to expand its portfolio.

The company has a wide presence across the Americas, Europe, Middle East, and Africa, and Asia-Pacific. The company also has various subsidiary companies such Guidant (U.S.), Vertiflex (U.S.), American Medical Systems, Inc. (U.S.), Augmenix Inc. (U.S.), Symetis SA (Switzerland), among others.

STERIS

STERIS was founded in 1985, headquartered in Ohio, U.S. The company engages in the provision of healthcare and life science product and service solutions. It has the following business segments Healthcare, Applied Sterilization Technologies, and Life Sciences, in which Healthcare is the market-focused segment. The company also provides various product categories, including Hospitals and Surgery Centers, Medical Device, Pharmaceutical and Biotechnology Manufacturers, and Research Laboratory. The market-focus products lie under Hospitals and Surgery Centers. The company has initiated many strategic initiatives to expand its market.

For instance,

• In January 2021, STERIS announced that it has agreed to acquire Cantel, a global provider of endoscopy products. The acquisition will help the company to expand its endoscopy product portfolio.

The company has a wide presence across the Americas, Europe, Asia-Pacific, Middle East, and Africa. The company has various subsidiary companies such as Cantel Medical Corporation (U.S.), Synergy Health (U.K.), Isomedix Inc. (U.S.), US Endoscopy Inc. (U.S.), Steris Private Limited (India), among others.